Clinical trials: Adrenal Tumor
Urologic Diseases, Adrenal Tumor
Rare Cystic Benign Adrenal Incidentalomas
Benign complex cystic and vascular adrenal tumors comprise a group of lesions characterized by significant rarity. But, their detection is increasing due to improved radiologic imaging techniques.
- Trial name
- NCT03739918
- Where
- Egypt
- Volunteers
- 291 people
- Sponsor
- Mansoura University
Adrenocortical Carcinoma, Peritoneal Carcinomatosis
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare tumor with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 months.
- Trial name
- NCT03127774
- Testing
- Cisplatin, Sodium thiosulfate, Cytoreductive surgery
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Columbia University
Stage IV Adrenocortical Carcinoma
Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
Current therapies for Stage IV adrenal gland cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV adrenal gland…
- Trial name
- NCT00003453
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Burzynski Research Institute
Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma
Ivonescimab in the Treatment of Multiple Advanced Tumors
The goal of this clinical trial is to learn if Ivonescimab works to treat advanced rare tumors including cohort 1: PAGET's disease of scrotum with infiltrating sweat gland carcinoma.
- Conditions
- Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma
- Trial name
- NCT06683846
- Testing
- Ivocizumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fudan University
Adrenocortical Carcinoma
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
Background: Adrenocortical carcinoma (ACC) is a rare cancer. It has a poor prognosis. Some people live with ACC for years; others live for just months. The average survival from the time of diagnosis is 14.5 months.
- Trial name
- NCT04358107
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Adrenal Tumors
Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation
The purpose of this study is to evaluate changes in adrenal hormones during adrenal radiofrequency (RF) ablation.
- Trial name
- NCT00997594
- Testing
- Radiofrequency ablation
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Mie University
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Adrenocortical Carcinoma, Pheochromocytoma
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ACC or PPGL.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT07743138
- Testing
- Ivonescimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma, Adrenal Tumor
Research on the Effectiveness and Safety of Remote Control of Domestic Surgical Robot System for Urinary Surgery
One-arm clinical trial was adopted in this study. The surgeon performed remote urological surgery for patients through domestically produced "MicroHand" surgical robot system (Shandong Weigao Co., Ltd).
- Conditions
- Renal Cell Carcinoma, Adrenal Tumor, Nonfunctioning Kidney
- Trial name
- NCT04804163
- Testing
- telesurgery by domestic robot
- Where
- China
- Volunteers
- 47 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Adrenal Tumors, Adrenal Malignancies
Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)
The purpose of this study is to find out if your adrenal glands are normal or abnormal. This can be determined by whether or not your adrenal gland concentrates more of a labeled building block of adrenal hormone, norcholesterol.
- Conditions
- Adrenal Tumors, Adrenal Malignancies, Abnormal Hormonal Secretions, Electrolytes Abnormalities
- Trial name
- NCT00591643
- Testing
- Imaging, Adrenal acans, (NP-59)
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liver Cancer
Chemotherapy in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003044
- Testing
- cisplatin-e therapeutic implant
- Where
- 3 sites in United States, Hong Kong
- Volunteers
- 55 people
- Sponsor
- Matrix Pharmaceutical
Adrenal Tumor, Adrenal Adenoma
Laparoscopic Adrenalectomy for Large Adrenal Tumors.
Laparoscopic adrenalectomy is the treatment of choice for the benign tumor of less than 6 cm. However, this is an ongoing debate that exact cut-off value of tumor size for LA.
- Trial name
- NCT03830593
- Testing
- Laparoscopic Adrenalectomy
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Samsun Liv Hospital
Adrenal Tumor, Adrenalectomy; Status
3D Laparoscopic Adrenalectomies for Adrenal Tumors
The main drawbacks of conventional 2D laparoscopy are limited depth perception and loss of spatial orientation. High-quality 3D laparoscopy systems might improve surgical outcomes for adrenalectomy.
- Trial name
- NCT04905706
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Adrenal Gland Diseases, Adrenal Gland Neoplasms
Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening
This is a clinical research study using I-131 Iodocholesterol which is an experimental radioactive chemical that when injected into the vein, is picked up in the adrenal glands and permits visualization with gamma imaging…
- Trial name
- NCT00037843
- Testing
- I-131 Iodocholesterol
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- M.D. Anderson Cancer Center
Pheochromocytoma, Metastatic, Pheochromocytoma Malignant
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor. Penpulimab is specifically an immune check-point inhibitor of PD1 and has been approved for the treatment of several malignancies.This phase…
- Conditions
- Pheochromocytoma, Metastatic, Pheochromocytoma Malignant, Paraganglioma, Malignant
- Trial name
- NCT05885399
- Testing
- Penpulimab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Peking Union Medical College Hospital
Primary Aldosteronism, Essential Hypertension
The Plasma Metabolomics Profiling of Primary Aldosteronism
Primary aldosteronism (PA), characterized by overt renin-independent aldosterone production, is the most common form endocrine hypertension.
- Conditions
- Primary Aldosteronism, Essential Hypertension, Idiopathic Aldosteronism, Aldosterone-producing Adenoma
- Trial name
- NCT06500000
- Testing
- liquid chromatography-mass spectrometry (LC/MS)
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Third Military Medical University
Cancer
A Pilot Study of Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney or Isolated Adrenal Metastases
This is a "proof of concept" study, to assess the feasibility of introducing a novel high-precision radiotherapy technique called "stereotactic radiosurgery" (SRS) or "stereotactic body radiotherapy" (SBRT) for the treatment of…
- Trial name
- FASTRACK (NCT01676428)
- Testing
- Radiotherapy
- Where
- Australia
- Volunteers
- 42 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
- Trial name
- NCT02592356
- Testing
- Computed Tomography, Dual X-ray Absorptiometry, Physical Examination
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center